Clinical Trials Browser

Phase 1 × HER2 Negative Metastatic Breast Cancer × ADI PEG20 × Clear all

NCT01948843 2016-04-14

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

Phase 1 Completed

HER2 Negative Metastatic Breast Cancer